Mark Fishman started heading up research & development (R&D) at Novartis, as President of the Novartis Institutes for BioMedical Research (NIBR), 10 years ago. Prior to joining the drug firm in 2002, Fishman worked as a cardiologist, with a research focus on using zebrafish as a model for cardiovascular disease. He has since, however, helped to usher in a focus on rare diseases and pathway-based research at Novartis. Speaking with Asher Mullard, he looked back on a decade of R&D at Novartis and discussed how R&D trends could evolve in the next 10 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mark Fishman. Nat Rev Drug Discov 11, 14–15 (2012). https://doi.org/10.1038/nrd3640
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3640
